ORIC PHARMACEUTICALS, INC. Net Fee Amt
ORIC PHARMACEUTICALS, INC. (ORIC) had Net Fee Amt of $1.67 thousand as of 2026-07-30, per its S-8 filed 2026-07-30.
Financial Statements › Notes
ffd:NetFeeAmt · last filed 2026-07-30
- 2026-07-30: Net Fee Amt $1.67K.
| Period end | Net Fee Amt |
|---|---|
| 2026-07-30 | $1.67K S-8 · filed 2026-07-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Kardigan, Inc. (KARD) | United States | $1.346B | |
| Tyra Biosciences, Inc. (TYRA) | United States | $1.337B | -12.83 |
| Bicara Therapeutics Inc. (BCAX) | United States | $1.309B | -10.55 |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| OMEROS CORP (OMER) | United States | $1.456B | 5.50 |
| Ultragenyx Pharmaceutical Inc. (RARE) | United States | $1.456B | -5.62 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| ArriVent BioPharma, Inc. (AVBP) | United States | $1.485B | -10.25 |
| Innoviva, Inc. (INVA) | United States | $1.493B | 4.62 |